Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Obseva Sa (OBSV)

Obseva Sa (OBSV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,078
  • Shares Outstanding, K 47,999
  • Annual Sales, $ 0 K
  • Annual Income, $ -108,790 K
  • 60-Month Beta 0.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.37
  • Number of Estimates 4
  • High Estimate -0.36
  • Low Estimate -0.38
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +53.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.43 +1.23%
on 09/25/20
3.06 -19.61%
on 09/04/20
-0.21 (-7.87%)
since 08/25/20
3-Month
2.43 +1.23%
on 09/25/20
6.30 -60.95%
on 07/02/20
-3.49 (-58.66%)
since 06/25/20
52-Week
1.63 +50.92%
on 03/16/20
9.62 -74.43%
on 09/26/19
-6.10 (-71.26%)
since 09/25/19

Most Recent Stories

More News
ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020

OBSV : 2.46 (-0.81%)
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 Million

OBSV : 2.46 (-0.81%)
ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 - 12, 2020

OBSV : 2.46 (-0.81%)
ObsEva Announces Second Quarter 2020 Financial Results and Business Update

OBSV : 2.46 (-0.81%)
ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids

Geneva, Switzerland and Boston, MA - June 29, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive...

OBSV : 2.46 (-0.81%)
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020

Geneva, Switzerland and Boston, MA - June 9, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 2.46 (-0.81%)
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis

GENEVA, Switzerland and BOSTON, MA (June 4, 2020) - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health,...

OBSV : 2.46 (-0.81%)
ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020

Geneva, Switzerland and Boston, MA - May 29, 2020 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health,...

OBSV : 2.46 (-0.81%)
ObsEva Annual General Meeting 2020

OBSV : 2.46 (-0.81%)
ObsEva Announces First Quarter 2020 Financial Results and Business Update

OBSV : 2.46 (-0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade OBSV with:

Business Summary

ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland.

See More

Key Turning Points

2nd Resistance Point 2.57
1st Resistance Point 2.52
Last Price 2.46
1st Support Level 2.42
2nd Support Level 2.37

See More

52-Week High 9.62
Fibonacci 61.8% 6.57
Fibonacci 50% 5.63
Fibonacci 38.2% 4.68
Last Price 2.46
52-Week Low 1.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar